| Company/Division name | WuXi Biologics |
| Parent company | WuXi Biologics |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 200 |
| Year reshoring announced: | 2024 |
| Year reshoring implemented or to be implemented: | 2025 |
| Country(ies) from which reshored: | China |
| City reshored to: | Worcester |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | commercial drug substance |
| What domestic positive factors made reshoring more attractive? | Higher productivity, Lead time/Time to market, Manufacturing/engineering joint innovation (R&D) |
